Deprenyl PDF Download

Author: Alastair Dow
Publisher:
ISBN: 9780873190367
Category : Medical
Languages : en
Pages : 268

View

Book Description

Author:
Publisher:
ISBN: 9789993492511
Category :
Languages : en
Pages :

View

Book Description

Author: Joseph Knoll
Publisher: Bentham Science Publishers
ISBN: 1608054705
Category : Medical
Languages : en
Pages : 161

View

Book Description
This e-book is a reference on Selegiline ((-)-Deprenyl) effects on the brain. Selegiline, described in thousands of research papers, is registered in over 60 countries. At present, more than one hundred preparations containing selegiline circulate in the global market under different brand names. They are widely used in the treatment of Parkinson's disease, Alzheimer's disease, major depression and as a geroprotective / anti-aging drug. ((-)-Deprenyl) selegiline, the first selective inhibitor of B-type MAO which, in contrast to the known MAO inhibitors, did not potentiate the effect of tyramine but inhibited it. the compound could be combined with levodopa in Parkinson's disease without signs of hypertensive reactions. the DATATOP study in the USA revealed that (-)-deprenyl delayed the onset of disability associated with early, otherwise untreated Parkinson's disease. the age-related decay of the supply of the brain with phenylethylamine (PEA), due to the progressive increase of MAO-B activity in the aging brain, and dopamine, due to the better than average decline of the dopaminergic neuronal activity during the postdevelopmental phase of life, are irresistible biochemical lesions of aging. the speed of deterioration of behavioral performances with the passing of time and longevity depends significantly on the pace of the worsening of these lesions. (-)-Deprenyl, increasing the supply of the brain with PEA and dopamine, counteracts this aging process. Maintenance of male rats from sexual maturity until death on ((-)-deprenyl) delays the age-related loss of the capacity to ejaculate, slows the age-related decline of learning ability and prolongs life. In humans, maintenance from sexual maturity on (-)-deprenyl (1 mg daily) is, for the time being, the most promising prophylactic treatment to fight against the age-related decay of behavioral performances, prolonging life, and preventing or delaying the onset of age-related neurodegenerative diseases such as Parkinson's and Alzheimer's. This e-book is a useful reference for graduate medical students, academic researchers in the field of neuropsychopharmacology, neurophysiology and gerontology and professional research groups in commercial organizations manufacturing selegiline preparations.

Author:
Publisher: American Academy of Anti-Aging Med
ISBN: 9780966893731
Category : Family & Relationships
Languages : en
Pages : 288

View

Book Description

Author: Sharon L. Crowell-Davis
Publisher: John Wiley & Sons
ISBN: 0470344148
Category : Medical
Languages : en
Pages : 288

View

Book Description
Every day veterinarians in practice are asked to treat petsexhibiting problem behaviors. In the last several yearspharmacologic treatments of behavior have made significant advancesand can serve as a critical part of therapy. Veterinary Pscyhopharmacology is a complete source of currentknowledge on the subject of pharmacologic behavior modificationthat veterinarians can turn to for the answers they need. Classification of disorders is eschewed in favor of in-depthexplanations of pharmacologic options in inducing behavior changes.Special emphasis is given to explaining the underlying mechanism ofpharmacologic agents used in therapy; thus, veterinarians will knownot only which drugs to prescribe but why they should be prescribedand how they work. Veterinary behaviorists, their students and residents, veterinarypractitioners of all levels, and veterinary students will find thisbook invaluable in providing information about their patients'behavior problems and the psychoactive medications that might helpthem.

Author: Srdjan M Vlajkovic
Publisher:
ISBN: 9783036515069
Category :
Languages : en
Pages : 170

View

Book Description
The sense of hearing is vulnerable to environmental challenges, such as exposure to noise. More than 1.5 billion people experience some decline in hearing ability during their lifetime, of whom at least 430 million will be affected by disabling hearing loss. If not identified and addressed in a timely way, hearing loss can severely reduce the quality of life at various stages. Some causes of hearing loss can be prevented, for example from occupational or leisure noise. The World Health Organization estimates that more than 1 billion young people put themselves at risk of permanent hearing loss by listening to loud music over long periods of time. Mitigating such risks through public health action is essential to reduce the impact of hearing loss in the community. The etiology of sensorineural hearing loss is complex and multifactorial, arising from congenital and acquired causes. This book highlights the diverse range of approaches to sensorineural hearing loss, from designing new animal models of age-related hearing loss, to the use of microRNAs as biomarkers of cochlear injury and drug repurposing for the therapy of agerelated and noise-induced hearing loss. Further investigation into the underlying molecular mechanisms of sensorineural hearing loss and the integration of the novel drug, cell, and gene therapy strategies into controlled clinical studies will permit significant advances in a field where there are currently many unmet needs.

Author: Peter Riederer
Publisher: Springer Nature
ISBN: 303062059X
Category : Medical
Languages : en
Pages : 4652

View

Book Description
This book provides a reference guide describing the current status of medication in all major psychiatric and neurological indications, together with comparisons of pharmacological treatment strategies in clinical settings in Europe, USA, Japan and China. In addition, it highlights herbal medicine as used in China and Japan, as well as complementary medicine and nutritional aspects. This novel approach offers international readers a global approach in a single dedicated publication and is also a valuable resource for anyone interested in comparing treatments for psychiatric disorders in three different cultural areas. There are three volumes devoted to Basic Principles and General Aspects, offering a general overview of psychopharmacotherapy (Vol. 1); Classes, Drugs and Special Aspects covering the role of psychotropic drugs in the field of psychiatry and neurology (Vol. 2) and Applied Psychopharmacotherapy focusing on applied psychopharmacotherapy (Vol. 3). These books are invaluable to psychiatrists, neurologists, neuroscientists, medical practitioners and clinical psychologists.

Author: Ronald Klatz
Publisher: Mary Ann Liebert
ISBN:
Category : Health & Fitness
Languages : en
Pages : 426

View

Book Description

Author: Abraham N. Lieberman
Publisher: Simon and Schuster
ISBN: 0671768190
Category : Health & Fitness
Languages : en
Pages : 276

View

Book Description
A guide for Parkinson patients and their caregivers that addresses the body and the spirit.

Author: David Finkelstein
Publisher: IntechOpen
ISBN: 9789533074634
Category : Medical
Languages : en
Pages : 410

View

Book Description
Parkinson's disease (PD) is characterised clinically by various non-motor and progressive motor symptoms, pathologically by loss of dopamine producing cells and intraneuronal cytoplasmic inclusions composed primarily of ?-synuclein. By the time a patient first presents with symptoms of Parkinson's disease at the clinic, a significant proportion of the cells in the substantia nigra have already been destroyed. This degeneration progresses despite the current therapies until the cell loss is so great that the quality of normal life is compromised. The dopamine precursor levodopa is the most valuable drug currently available for the treatment of PD. However for most PD patients, the optimal clinical benefit from levodopa decreases around five to six years of treatment. The aim of the chapters of this book is to work towards an understanding in the mechanisms of degeneration and to develop disease modifying therapies.